, 67:893 | Cite as

Simultaneous Determination of Tamsulosin and Dutasteride in Human Plasma by LC–MS–MS

  • Sangita Agarwal
  • K. Veeran Gowda
  • Amlan Kanti Sarkar
  • Debotri Ghosh
  • Uttam Bhaumik
  • Tapas Kumar Chattaraj
  • Tapan Kumar Pal


A sensitive and selective liquid chromatographic tandem mass spectrometric (LC–MS–MS) method was developed for simultaneous identification and quantification of tamsulosin and dutasteride in human plasma, which was well applied to clinical study. The method was based on liquid–liquid extraction, followed by an LC procedure with a Gemini C-18, 50 mm × 2.0 mm (3 μm) column and using methanol:ammonium formate (97:3, v/v) as the mobile phase. Protonated ions formed by a turbo ionspray in positive mode were used to detect analytes and internal standard. MS–MS detection was by monitoring the fragmentation of 409.1 → 228.1 (m/z) for tamsulosin, 529.3 → 461.3 (m/z) for dutasteride and 373.2 → 305.3 (m/z) for finasteride (IS) on a triple quadrupole mass spectrometer. The lower limit of quantification for both tamsulosin and dutasteride was 1 ng mL−1. The proposed method enables the unambiguous identification and quantification of tamsulosin and dutasteride for clinical drug monitoring.


Column liquid chromatography–mass spectrometry Pharmacokinetics Validation Tamsulosin and dutasteride 



The authors are thankful to DPRP/PRDSF of Department of Science and Technology (DST), New Delhi (Grant No.VII-PRDSF/56/05-06/TDT) for providing the instrumental facilities and financial support for carrying out this study and also to Burgeon Pharmaceutical Pvt. Ltd., Chennai, India for supplying the samples.


  1. 1.
    Wei JT, Calhoun E, Jacobsen SJ (2005) J Urol 173:1256CrossRefGoogle Scholar
  2. 2.
    Sarma AV, Jacobson DJ, McGree ME et al (2005) J Urol 173:2048CrossRefGoogle Scholar
  3. 3.
    Sung JC, Curtis LH, Schulman KA, Albala DM (2006) J Urol 175:1023CrossRefGoogle Scholar
  4. 4.
    Gilling PJ, Cass CB, Cresswell MD, Malcolm AR, Fraundorfer MR (1996) J Endourol 10:459–461CrossRefGoogle Scholar
  5. 5.
    Kuo RL, Paterson RF, Kim SC, Siqueira TM Jr, Elhilali MM, Lingeman JE (2003) World J Surg Oncol 1:6CrossRefGoogle Scholar
  6. 6.
    McVary KT (2007) Clin Ther 29:387CrossRefGoogle Scholar
  7. 7.
    Honda K, Nakagawa C (1986) J Pharmacol Exp Ther 239:512Google Scholar
  8. 8.
    Honda K, Nakagawa C, Terai M, Naunyn S (1987) Arch Pharmacol 336:295CrossRefGoogle Scholar
  9. 9.
    Soeishi Y, Kobori M, Kobayashi SL, Higuchi S (1990) J Chromatogr B 533:290Google Scholar
  10. 10.
    Matsushima H, Takanuki KI, Kamimura H, Watanabe T, Higuchi S (1997) J Chromatogr B 695:317CrossRefGoogle Scholar
  11. 11.
    Dinga L, Limin L, Taob P, Yanga J, Zhengxing Z (2002) J Chromatogr B 767:75–81CrossRefGoogle Scholar
  12. 12.
    Ramakrishna NVS, Vishwottam KN, Puran S, Manoj S, Santosh M, Wishu S, Koteshwara M, Chidambara J, Gopinadh B, Sumatha B (2004) J Chromatogr B 805:13–20CrossRefGoogle Scholar
  13. 13.
    Lee MS, Kerns EH (1999) Mass Spectrom Rev 18:187CrossRefGoogle Scholar
  14. 14.
    Niessen WMA (2003) J Chromatogr A 1000:413CrossRefGoogle Scholar
  15. 15.
    Macek J, Klima J, Ptacek P (2004) J Chromatogr B 809:307–311Google Scholar
  16. 16.
    Guidance for Industry: Bioanalytical Method Validation (2001) US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MDGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2008

Authors and Affiliations

  • Sangita Agarwal
    • 1
  • K. Veeran Gowda
    • 1
  • Amlan Kanti Sarkar
    • 1
  • Debotri Ghosh
    • 1
  • Uttam Bhaumik
    • 1
  • Tapas Kumar Chattaraj
    • 2
  • Tapan Kumar Pal
    • 1
  1. 1.Department of Pharmaceutical TechnologyJadavpur UniversityKolkataIndia
  2. 2.N.R.S. Medical College and HospitalKolkataIndia

Personalised recommendations